Market open
Monte Rosa Therapeutics/$GLUE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
$GLUE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
133
Website
GLUE Metrics
BasicAdvanced
$580M
Market cap
-
P/E ratio
-$1.77
EPS
1.30
Beta
-
Dividend rate
Price and volume
Market cap
$580M
Beta
1.3
52-week high
$10.11
52-week low
$3.21
Average daily volume
1.4M
Financial strength
Current ratio
6.033
Quick ratio
5.83
Long term debt to equity
19.494
Total debt to equity
21.269
Management effectiveness
Return on assets (TTM)
-28.43%
Return on equity (TTM)
-61.23%
Valuation
Price to revenue (TTM)
42.631
Price to book
2.82
Price to tangible book (TTM)
2.82
Price to free cash flow (TTM)
-10.168
Growth
Earnings per share change (TTM)
-34.40%
3-year earnings per share growth (CAGR)
-29.85%
What the Analysts think about GLUE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
GLUE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GLUE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GLUE News
AllArticlesVideos
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
GlobeNewsWire·9 hours ago
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
GlobeNewsWire·9 hours ago
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $580M as of December 11, 2024.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of December 11, 2024.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.